drugset / Trial / NCT07042165
Treatment of Bile Acid Diarrhoea With Atorvastatin
Phase 4
Recruiting
20 enrolled
Asger Lund, MD
Aase and Ejnar Danielsens Foundation · collabFonden til Lægevidenskabens Fremme · collabLæge Sofus Carl Emil Friis og Hustru Olga Doris Friis' Legat · collabProsektor Axel Søeborg Ohlsens Mindelegat · collab
RandomizedCrossoverDouble-blindTreatment
Summary
Bile acid diarrhoea (BAD) is a socially debilitating disease with stomach pain, high stool frequency, urgency, and faecal incontinence as the main symptoms. Studies estimate that 1-2% of the population suffers from the disease. There is an unmet need for more treatment options in patients suffering from BAD. The investigators hypothesise that atorvastatin treatment lowers bile acid synthesis in patients with bile acid diarrhoea. The investigators will investigate this hypothesis in the current study, BASTA, which is a Randomised, Double-Blind, Placebo-Controlled, Crossover, Proof of Concept, Investigator-Initiated, Trial.
Timeline
- Start
- 2025-10-15
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 80 mg | Oral |